This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bianco, T M
Right arrow Articles by Bertino, J S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bianco, T M
Right arrow Articles by Bertino, J S, Jr

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1989 November; 33(11): 1890-1895

Gentamicin pharmacokinetics, nephrotoxicity, and prediction of mortality in febrile neutropenic patients.

T M Bianco, P N Dwyer and J S Bertino Jr

Department of Pharmacy Services, Mary Imogene Bassett Hospital, Cooperstown, New York 13326.

ABSTRACT

The pharmacokinetics of gentamicin in 34 febrile neutropenic patients (40 courses) were compared with those in 40 nonneutropenic patients receiving the drug. No pharmacokinetic differences were seen in half-life, volume of distribution (liter per kilogram; total and ideal body weight), or clearance (milliliter per minute per 1.73 m2). The incidences of nephrotoxicity in the two groups were not statistically different. Because of the small number of patients with positive cultures, no relationship between initial peak serum gentamicin concentration and mortality could be determined. Mortality risk factors that were determined to be statistically important included presence of pneumonia, persistent fever in the presence of anti-infective therapy of more than 1 week duration, and peak serum creatinine of greater than 1.2 mg/dl. Initial aminoglycoside dosing in the febrile neutropenic patient should be similar to that in the nonneutropenic patient, with concentrations in serum monitored and doses adjusted accordingly.


Antimicrob Agents Chemother. 1989 November; 33(11): 1890-1895




This article has been cited by other articles:

  • Oliveira, J. F. P., Silva, C. A., Barbieri, C. D., Oliveira, G. M., Zanetta, D. M. T., Burdmann, E. A. (2009). Prevalence and Risk Factors for Aminoglycoside Nephrotoxicity in Intensive Care Units. Antimicrob. Agents Chemother. 53: 2887-2891 [Abstract] [Full Text]